- Home
- ACAD vs GHC Comparison
ACAD vs GHC Comparison
Compare ACAD & GHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- GHC
- Stock Information
- Founded
- ACAD 1993
- GHC 1877
- Country
- ACAD United States
- GHC United States
- Employees
- ACAD N/A
- GHC N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- GHC Other Consumer Services
- Sector
- ACAD Health Care
- GHC Real Estate
- Exchange
- ACAD Nasdaq
- GHC Nasdaq
- Market Cap
- ACAD 3.5B
- GHC 4.2B
- IPO Year
- ACAD 2004
- GHC N/A
- Fundamental
- Price
- ACAD $23.53
- GHC $921.67
- Analyst Decision
- ACAD Buy
- GHC
- Analyst Count
- ACAD 18
- GHC 0
- Target Price
- ACAD $27.94
- GHC N/A
- AVG Volume (30 Days)
- ACAD 1.7M
- GHC 40.4K
- Earning Date
- ACAD 08-06-2025
- GHC 07-30-2025
- Dividend Yield
- ACAD N/A
- GHC 0.78%
- EPS Growth
- ACAD N/A
- GHC 426.70
- EPS
- ACAD 1.37
- GHC 155.13
- Revenue
- ACAD $996,283,000.00
- GHC $4,834,649,000.00
- Revenue This Year
- ACAD $13.28
- GHC $0.54
- Revenue Next Year
- ACAD $10.88
- GHC $6.39
- P/E Ratio
- ACAD $17.19
- GHC $5.93
- Revenue Growth
- ACAD 22.42
- GHC 4.73
- 52 Week Low
- ACAD $13.40
- GHC $691.41
- 52 Week High
- ACAD $25.23
- GHC $1,015.00
- Technical
- Relative Strength Index (RSI)
- ACAD 61.47
- GHC 48.67
- Support Level
- ACAD $22.40
- GHC $882.21
- Resistance Level
- ACAD $24.06
- GHC $966.85
- Average True Range (ATR)
- ACAD 0.72
- GHC 18.84
- MACD
- ACAD 0.09
- GHC 5.08
- Stochastic Oscillator
- ACAD 76.96
- GHC 46.62
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About GHC Graham Holdings Company
Graham Holdings Co. is a diversified education and media company made up of subsidiaries. Firm operations include educational services; television broadcasting; online, print, and local news; home health and hospice care; and manufacturing. The Company segments into the following seven reportable segments: Kaplan International, Higher Education, Supplemental Education, Television Broadcasting, Manufacturing, Healthcare, and Automotive. The majority of revenue comes from the Kaplan International segment, which includes higher education, test preparation, language instruction, and professional training. A large portion of company revenue also comes from the television broadcasting segment through advertising.